Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT04836117Not ApplicableTerminated

Evaluating the Impact of SomaSignal Tests on Medical Management and Change in Risk in Patients at Higher Risk of Cardiovascular Disease: A Feasibility and an Adaptive Implementation Study

Role: collaborator

NCT05166382Not ApplicableCompleted

Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications

Role: collaborator

NCT05256706Not ApplicableCompleted

SomaSignal Tests on Medical Management and Change in Risk in Patients With Diabetes

Role: collaborator

NCT05182359Not ApplicableCompleted

Pragmatic Impact of Proteomic Risk Stratification in Diabetes Mellitus

Role: collaborator

NCT05237271Not ApplicableCompleted

Clinical Utility Trial for the SomaLogic CVD-T2D Test

Role: collaborator

NCT03599531Completed

Utility of the SomaLogic Cardiovascular Disease (CVD) Secondary Risk Panel for Cardiovascular Risk

Role: lead

NCT01125501Not ApplicableWithdrawn

Protandim and the Metabolic Syndrome

Role: lead

All 7 trials loaded